← Back to Clinical Trials
Recruiting NCT06580340

NCT06580340 Effectiveness of an Adapted Physical Activity Program for Subjects Suffering From Haemophilia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06580340
Status Recruiting
Phase
Sponsor Istituto Ortopedico Rizzoli
Condition Hemophilia
Study Type INTERVENTIONAL
Enrollment 16 participants
Start Date 2024-09-10
Primary Completion 2025-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
AFA (Adapted Physical Activity)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 16 participants in total. It began in 2024-09-10 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The present study aims to evaluate the modification of functional capacity induced by an adapted physical activity program in subjects with haemophilia. The exercise program used aims to improve joint mobility, muscle strength, static and dynamic balance, motor coordination. The program is structured in 1 hour sessions of 2 days/week and lasts 6 months. The primary endpoint is the change in functional capacity calculated as the difference between the baseline assessment and the 3 and 6 month assessment of the 6 Minutes Walking Test measured with the G-Walk (BTS Bioengineering S.p.A).

Eligibility Criteria

Inclusion Criteria: * Diagnosis of hemophilia A or B; * Signature of informed consent; * Availability of a medical certificate for non-competitive activities Exclusion Criteria: * Active bleeding * Severe joint deformities that prevent exercise * Insufficiency of communicative and/or sensory functions so severe that it is impossible to understand or carry out the trainer's instructions (dementia, aphasia, blindness, deafness) * Heart failure (NYHA class \> 2) * Unstable angina * Lung disease requiring oxygen therapy * Symptomatic peripheral arterial disease * Myocardial infarction or hospitalization within the previous 6 months * Symptomatic orthostatic hypotension * Hypertension in poor pharmacological control (diastolic\> 95 mmHg, systolic\> 160 mmHg) * Significant neurological conditions that impair motor or cognitive function

Frequently Asked Questions

Who can join the NCT06580340 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Hemophilia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06580340 currently recruiting?

Yes, NCT06580340 is actively recruiting participants. Visit ClinicalTrials.gov or contact Istituto Ortopedico Rizzoli to inquire about joining.

Where is the NCT06580340 trial being conducted?

This trial is being conducted at Bologna, Italy.

Who is sponsoring the NCT06580340 clinical trial?

NCT06580340 is sponsored by Istituto Ortopedico Rizzoli. The trial plans to enroll 16 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology